Magnussen_2015_Eur.J.Pharmacol_762_35

The neuronal alpha7 nicotinic acetylcholine receptor is a homo-pentameric ligand-gated ion channel that is a promising drug target for cognitive deficits in Alzheimers disease and schizophrenia. We have previously described (11)C-NS14492 as a suitable agonist radioligand for in vivo positron emission tomography (PET) occupancy studies of the alpha7 nicotinic receptor in the pig brain. In order to investigate the utility of the same compound for in vitro studies, (3)H-NS14492 was synthesized and its binding properties were characterized using in vitro autoradiography and homogenate binding assays in pig frontal cortex. (3)H-NS14492 showed specific binding to alpha7 nicotinic receptors in autoradiography, revealing a dissociation constant (Kd) of 2.1+/-0.7nM and a maximum number of binding sites (Bmax) of 15.7+/-2.0fmol/mg tissue equivalent. Binding distribution was similar to that of another selective ligand (125)I-alpha-bungarotoxin ((125)I-BTX) in autoradiography, and unlabeled NS14492 displaced (125)I-BTX with an inhibition constant (Ki) of 23nM. (3)H-NS14492 bound to alpha7 nicotinic receptors in homogenized pig frontal cortex with a Kd of 0.8+/-0.3nM and a Bmax of 30.2+/-11.6fmol/mg protein. This binding assay further revealed the Ki rank order for a number of alpha7 nicotinic receptor agonists, and positive allosteric modulators (PAMs). Further, we saw increased binding of (3)H-NS14492 to pig frontal cortex membranes when co-incubated with PNU-120596, a type II PAM. Taken together, these findings show that (3)H-NS14492 is a useful new in vitro radioligand for the pig alpha7 nicotinic receptor.